Table 4.
Univariable and multivariable analysis of OS in the MVR group.
| Variables | Univariable analysis | Multivariable analysis | |
|---|---|---|---|
| P value | HR (95% CI) | P value | |
| Age, y (≤60/>60) | 0.734 | ||
| Sex (Male/Female) | 0.744 | ||
| Cirrhosis (yes/no) | 0.202 | ||
| Ascites (yes/no) | 0.295 | ||
| Splenomegaly (yes/no) | 0.034 | 1.339 (1.059-1.692) | 0.015 |
| ICGR 15 (≤10%/>10%) | 0.939 | ||
| Tumor capsule (yes/no) | 0.153 | ||
|
Up-to-seven criteria
(beyond/within) |
0.001 | 1.430 (1.110-1.844) | 0.006 |
| AFP, ug/L (≤20/>20) | 0.100 | ||
| GGT, u/L (≤50/>50) | 0.795 | ||
| AST, u/L (≤40/>40) | 0.886 | ||
| ALT, u/L (≤40/>40) | 0.532 | ||
| Albumin, g/L (≤30/>30) | 0.303 | ||
| TBIL, umol/L (>20.5/≤20.5) | 0.163 | ||
| PT, sec (≤14/>14) | 0.762 | ||
| WBC, 109/L (≤4/>4) | 0.721 | ||
| HB, g/L (≤120/>120) | 0.336 | ||
| Platelet count, 109/L (≤100/>100) | 0.158 | ||
| Sorafenib after TACE (yes/no) | 0.001 | 0.668 (0.533-0.838) | <0.001 |
| Radical therapy after TACE (yes/no) | 0.013 | 0.586 (0.392-0.877) | 0.009 |